Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ

$1.72

-33%
HealthcareBiotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

At a Glance

Live Snapshot
Market Cap$70.67M
EPS-0.2500
P/E Ratio-5.74
Earnings Date02/12/2026

aneb

Cash and Cash Equivalents

Last Annual Value

11.63M

3-Year CAGR

-7%

5-Year CAGR

31%

10-Year CAGR

14%

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Competitors Analysis of Cash and Cash Equivalents

ANEB · NASDAQ
CompanyCash and Cash Equivalents
CAGR 3Y
CAGR 5Y
CAGR 10Y
11.63M
1.1%-10.3%N/A 
CLNN logo
Clene Inc.
NASDAQ:CLNN
5.19M
-43.5%-36.5%N/A
93.93M
75.1%39.7%N/A
35.99M
8.7%-9.7%N/A
10.74M
-21.9%35.7%-12.0%
55.81M
-31.9%-17.5%N/A
EXOZ logo
eXoZymes, Inc.
NASDAQ:EXOZ
3.04M
257.5%40.9%N/A
81.54M
34.5%-3.1%N/A
45.95M
71.8%-9.9%28.0%
6.21M
-33.1%-38.3%N/A
48.91M
-20.2%2.7%N/A
Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Fair Value Envelope

ANEB · NASDAQ

Our analysis suggests that ANEB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.72, this represents a potential HIDDEN relative to our calculated worth for Anebulo Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $1.72